| Abstrakt: |
A recent study conducted at Vanderbilt University in Nashville, Tennessee, has found that blood eosinophils and fractional exhaled nitric oxide (F-ENO) can serve as prognostic and predictive biomarkers for childhood asthma. The study involved children aged 6 to 11 years with uncontrolled moderate-to-severe asthma who were given dupilumab, a medication used to treat asthma. The researchers discovered that higher levels of blood eosinophils and F-ENO were associated with an increased risk of exacerbations and a greater reduction in exacerbation rates. These findings suggest that blood eosinophil counts and F-ENO can be useful in identifying children at risk for asthma exacerbations and those who may respond well to dupilumab. The study was supported by Sanofi Pharmaceuticals Inc. [Extracted from the article] |
